Eli Lilly and Company — LLY
| Close Price | Market Cap | P/E Ratio | Forward P/E Ratio | Implied Growth* | Implied Forward Growth* | Dividend | P/B Ratio |
|---|
| $1051.99 | $992.40B | 45.7 | 25.1 | 20.4% | 13.6% | $6.23
0.6% | 35.5 |
Revenue & Net Income
|
Date |
Revenue |
Net_Income |
EPS |
Last_Updated |
Revenue_Change |
Net_Income_Change |
EPS_Change |
| 0 |
2020-12-31 |
$24,540M |
$6,194M |
$6.47 |
2024-05-27 15:34:39 |
N/A |
N/A |
N/A |
| 1 |
2021-12-31 |
$28,318M |
$5,582M |
$6.57 |
2026-02-13 08:40:17 |
15.4% |
-9.9% |
1.5% |
| 2 |
2022-12-31 |
$28,541M |
$6,245M |
$6.57 |
2026-02-27 22:00:39 |
0.8% |
11.9% |
0.0% |
| 3 |
2023-12-31 |
$34,124M |
$5,240M |
$5.82 |
2026-02-27 22:00:39 |
19.6% |
-16.1% |
-11.4% |
| 4 |
2024-12-31 |
$45,043M |
$10,590M |
$11.76 |
2026-02-27 22:00:39 |
32.0% |
102.1% |
102.1% |
| 5 |
2025-12-31 |
$65,179M |
$20,640M |
$23.08 |
2026-02-27 22:00:39 |
44.7% |
94.9% |
96.2% |
| 6 |
TTM 2025-12-31 |
$65,179M |
$20,640M |
$23.00 |
2026-02-06 08:37:31 |
0.0% |
0.0% |
-0.3% |
EPS
Forecasts
Y/Y % Change
YoY Growth Rates
LLY Year-over-Year Growth
| |
2020 |
2021 |
2022 |
2023 |
2024 |
2025 |
2026 |
2027 |
Average |
| Revenue Growth (%) |
|
15.4% |
0.8% |
19.6% |
32.0% |
44.7% |
25.7% |
14.3% |
21.8% |
| Revenue Analysts (#) |
0 |
0 |
0 |
0 |
0 |
0 |
6 |
6 |
|
| EPS Growth (%) |
|
-9.9% |
11.9% |
-16.1% |
102.1% |
94.9% |
54.8% |
23.9% |
37.4% |
| EPS Analysts (#) |
0 |
0 |
0 |
0 |
0 |
0 |
7 |
7 |
|
Expenses
| Year |
Revenue ($) |
Cost of Revenue ($) |
R&D ($) |
G&A ($) |
SG&A ($) |
Facilities / D&A ($) |
Personnel ($) |
| 2022 |
$28.5B |
$5.1B |
$7.2B |
$6.4B |
$6.4B |
$1.5B |
$-372.9M |
| 2023 |
$34.1B |
$5.6B |
$9.3B |
$7.4B |
$7.4B |
$1.5B |
$-461.9M |
| 2024 |
$45.0B |
$6.7B |
$11.0B |
$8.6B |
$8.6B |
$1.8B |
$-461.7M |
| 2025 |
$65.2B |
$9.1B |
$13.3B |
$0.0 |
$11.1B |
$2.0B |
$0.0 |
| TTM |
$65.2B |
$9.1B |
$13.3B |
$8.0B |
$11.1B |
$2.0B |
$-326.0M |
| Year |
Revenue Change (%) |
Cost of Revenue Change (%) |
R&D Change (%) |
G&A Change (%) |
SG&A Change (%) |
Facilities / D&A Change (%) |
Personnel Change (%) |
| 2023 |
19.56 |
8.77 |
29.51 |
14.95 |
14.96 |
0.30 |
23.87 |
| 2024 |
32.00 |
19.73 |
18.02 |
16.08 |
16.07 |
15.72 |
-0.04 |
| 2025 |
44.70 |
36.14 |
21.34 |
-100.00 |
29.09 |
13.02 |
-100.00 |
| TTM |
0.00 |
0.00 |
0.00 |
inf |
-0.00 |
0.00 |
-inf |
No unmapped expenses.
Balance Sheet
| |
Metric |
Value |
| 0 |
Total Assets |
$114,935M |
| 1 |
Cash |
$9,792M |
| 2 |
Total Liabilities |
$91,085M |
| 3 |
Total Debt |
$42,507M |
| 4 |
Total Equity |
$23,793M |
| 5 |
Debt to Equity Ratio |
1.79 |
EPS & Dividend
Valuation
| Share Price |
Treasury Yield |
Estimates |
Fair Value (P/E) |
Fair Value (P/S) |
Current P/S |
Current P/E |
| $1051.99 |
4.0% |
FINVIZ Growth: 27% |
Nicks: 7
Finviz: 78 |
Nick's: 0.000 |
15.2 |
45.7 |
| Basis |
Year |
Nicks Valuation |
Nicks vs Share Price |
Finviz Valuation |
Finviz vs Share Price |
| $23.00 EPS |
TTM |
$153.52 |
-85.4% |
$1794.71 |
70.6% |
| $33.86 EPS |
2026 |
$226.00 |
-78.5% |
$2642.13 |
151.2% |
| $41.96 EPS |
2027 |
$280.07 |
-73.4% |
$3274.18 |
211.2% |
Implied Growth
|
Average |
Median |
Std Dev |
Current |
Percentile |
|
TTM |
Forward |
TTM |
Forward |
TTM |
Forward |
TTM |
Forward |
TTM |
Forward |
| Timeframe |
|
|
|
|
|
|
|
|
|
|
| 1 Year |
22.05% |
17.23% |
21.95% |
17.00% |
1.51% |
1.78% |
20.10% |
13.35% |
6.8% |
1.1% |
| 3 Years |
22.05% |
17.23% |
21.95% |
17.00% |
1.51% |
1.78% |
20.10% |
13.35% |
6.8% |
1.1% |
| 5 Years |
22.05% |
17.23% |
21.95% |
17.00% |
1.51% |
1.78% |
20.10% |
13.35% |
6.8% |
1.1% |
| 10 Years |
22.05% |
17.23% |
21.95% |
17.00% |
1.51% |
1.78% |
20.10% |
13.35% |
6.8% |
1.1% |
← Back